Are the Direct Oral Anticoagulants Better for Patients with Low Time in the Therapeutic Range on Vitamin K Antagonist Therapy?

被引：0
|
作者：
Schaefer, Jordan K. [1 ]
Barnes, Geoffrey D. [2 ]
机构：
[1] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI USA
[2] Univ Michigan, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI USA
来源：
THROMBOSIS AND HAEMOSTASIS | 2024年 / 124卷 / 08期
关键词：
WARFARIN; NONADHERENCE; MANAGEMENT; ADHERENCE;
D O I：
10.1055/s-0044-1787299
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：791 / 794
页数：4
相关论文
共 50 条
  • [1] The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation
    Vinding, Naja Emborg
    Bonde, Anders Nissen
    Rorth, Rasmus
    Lamberts, Morten
    Olesen, Jonas Bjerring
    Gislason, Gunnar Hilmar
    Torp-Pedersen, Christian
    Kober, Lars
    Fosbol, Emit Loldrup
    EUROPACE, 2019, 21 (04): : 572 - 579
  • [2] Antiplatelet therapy, vitamin K antagonist and low time in therapeutic range in patients with atrial fibrillation: Highway to bleed
    Fauchier, Laurent
    Bisson, Arnaud
    Genet, Thibaud
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 252 : 110 - 111
  • [3] Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants
    Barcellona, Doris
    Mameli, Antonella
    Cornacchini, Simona
    Perra, Flaminia
    Diovaldi, Marina
    Farci, Nicola
    Moledda, Valentina
    Marongiu, Francesco
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 333 : 162 - 166
  • [4] Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
    Toorop, Myrthe M. A.
    Chen, Qingui
    Kruip, Marieke J. H. A.
    van der Meer, Felix J. M.
    Nierman, Melchior C.
    Faber, Laura
    Goede, Lies
    Cannegieter, Suzanne C.
    Lijfering, Willem M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (02) : 339 - 352
  • [5] Management implications associated with switching from vitamin K antagonist anticoagulants to direct oral anticoagulants
    Pia-Morandeira, Agustin
    Cinza-Sanjurjo, Sergio
    Portela-Romero, Manuel
    REVISTA ESPANOLA DE CARDIOLOGIA, 2022, 75 (04): : 345 - 347
  • [6] Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
    Malagu, Michele
    Longo, Filomena
    Marchini, Federico
    Sirugo, Paolo
    Capanni, Andrea
    Clo, Stefano
    Mari, Elisa
    Culcasi, Martina
    Bertini, Matteo
    BIOLOGY-BASEL, 2023, 12 (04):
  • [7] NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH THALASSEMIA
    Capanni, A.
    Clo, S.
    Sirugo, P.
    Guardigli, G.
    Bertini, M.
    Orazio, G.
    Malagu, M.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25
  • [8] VITAMIN K ANTAGONIST OR DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION: THE IMPORTANCE OF TIME IN THERAPEUTIC RANGE
    Vinding, Naja Emborg
    Bonde, Anders Nissen
    Rorth, Rasmus
    Lamberts, Morten
    Olesen, Jonas Bjerring
    Gislason, Gunnar
    Torp-Pedersen, Christian
    Kober, Lars
    Fosbol, Emil Loldrup
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 460 - 460
  • [9] Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients
    Laurent Lafarge
    Fouzi Khayi
    Anis Bel-Kamel
    Nicolas Charhon
    Laura Sarfati
    Benoit Falquet
    Michel Ducher
    Laurent Bourguignon
    Drugs & Aging, 2018, 35 : 569 - 574
  • [10] Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients
    Lafarge, Laurent
    Khayi, Fouzi
    Bel-Kamel, Anis
    Charhon, Nicolas
    Sarfati, Laura
    Falquet, Benoit
    Ducher, Michel
    Bourguignon, Laurent
    DRUGS & AGING, 2018, 35 (06) : 569 - 574
12345